Trial Profile
Special Drug Use-results Survey for long-term use of Trerief 50mg/day (TOMORROW-PD)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Aug 2020
Price :
$35
*
At a glance
- Drugs Zonisamide (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms TOMORROW-PD
- Sponsors Sumitomo Dainippon Pharma
- 05 Aug 2020 Status changed from recruiting to completed.
- 03 Feb 2020 Planned End Date changed from 31 Dec 2017 to 31 Aug 2017.
- 04 Feb 2015 New trial record